Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

UK debate over β-interferon prescribing continues

Abstract

T he licensing of β-interferons for the treatment of multiple sclerosis (MS) has created a dilemma for the UK National Health Service (NHS). There is now a therapy available for a disease where management has traditionally been limited to symptomatic treaments; however, it comes with a large price tag attached. At a time when rationing is becoming a reality in the NHS, how has the issue of β-interferon prescribing been handled and how are patients with MS faring? Delegates at a recent British Association of Pharmaceutical Physicians meeting* heard from representatives of 2 parties involved in this debate - the pharmaceutical industry and patients.

This is a preview of subscription content, log in to check access.

Additional information

* ‘Is the pharmaceutical industry providing the NHS with medicines it can afford?’ [London, UK; 31 March 1999]

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Wright, T. UK debate over β-interferon prescribing continues. Pharmacoecon. Outcomes News 217, 3–5 (1999). https://doi.org/10.1007/BF03280113

Download citation

Keywords

  • Multiple Sclerosis
  • Multiple Sclerosis Patient
  • National Health Service
  • Riluzole
  • Multiple Sclerosis Population